CLOs on the Move

VentiRx Pharmaceuticals

www.ventirx.com

 
VentiRx Pharmaceuticals Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.ventirx.com
  • 12481 High Bluff Dr Ste 200
    San Diego, CA USA 92130
  • Phone: 858.436.1530

Executives

Name Title Contact Details

Similar Companies

CellGenix USA

CellGenix USA is a Antioch, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tri State Surgical Supply

Tri State Surgical Supply is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OLIVIAGroup

OLIVIAGroup is a West Chester, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

BNBI

Managed by Battelle National Biodefense Institute (BNBI) as a Federally Funded Research and Development Center (FFRDC), National Biodefense Analysis and Countermeasures Center is the first laboratory built for DHS – a national resource to understand th...

Zymeworks

Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks` suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks` lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks` second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks` proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.